2022 Annual Meeting | C81 - Motor Neuron Disease

Date Monday 04/04/22

Time 03:30 PM - 05:30 PM PDT Add To Calendar

Session Format This program will be presented both in-person and online

On Demand This program will be available in the meeting's On Demand product.

Event Type Seminar

Director(s) Eva Feldman, MD, PhD, FAAN

Topic(s) Neuromuscular and Clinical Neurophysiology (EMG)

Learning Objectives Participants should become familiar with ALS diagnostics, management in the telehealth era, and the latest clinical trials.

CME Available 2.00 CME credits

Core Competencies Medical Knowledge

Program Level Intermediate

Recommended Audience Specialist Neurologist

Teaching Styles Didactic

Program Materials Program Evaluations

Event Timeline
03:30 PM - 04:00 PM PDT	Speaker	The Diagnosis and Management of ALS in 2022 Stephen Goutman, MD, FAAN
03:30 PM - 03:30 PM PDT	Speaker	walk in slides Eva Feldman, MD, PhD, FAAN
04:00 PM - 04:30 PM PDT	Speaker	Telehealth and ALS: A Look Toward the Future Zachary Simmons, MD, FAAN
04:30 PM - 05:00 PM PDT	Speaker	Current and Emerging Clinical Trials in ALS Eva Feldman, MD, PhD, FAAN
05:00 PM - 05:30 PM PDT	Discussion	Panel Discussion Eva Feldman, MD, PhD, FAAN, Stephen Goutman, MD, FAAN, Zachary Simmons, MD, FAAN

Faculty Disclosures
Eva Feldman, MD, PhD, FAAN	The institution of Dr. Feldman has received research support from National Institutes of Health. The institution of Dr. Feldman has received research support from Centers for Disease Control and Prevention / Agency for Toxic Substances and Disease Registry. The institution of Dr. Feldman has received research support from Juvenile Diabetes Research Foundation. Dr. Feldman has received intellectual property interests from a discovery or technology relating to health care. Dr. Feldman has a non-compensated relationship as a Editorial Board Member with Journal of the Peripheral Nervous System, Experimental Neurology, Nature Neurology Reviews, Neurobiology of Disease, NeuroRx, Journal of Neurology Neurosurgery and Psychiatry, Scientific Reports, Lancet Neurology, Med (Cell Press Journal) that is relevant to AAN interests or activities. Dr. Feldman has a non-compensated relationship as a Editor-in-Chief with Oxford University Press Contemporary Neurology Series that is relevant to AAN interests or activities. Dr. Feldman has a non-compensated relationship as a Membership Committee Member, Strategic Planning Committee Member, and Chair of Section 07 with National Academy of Medicine that is relevant to AAN interests or activities. Dr. Feldman has a non-compensated relationship as a Associate Editor with Annals of Neurology that is relevant to AAN interests or activities. Dr. Feldman has a non-compensated relationship as a Governance Committee Chair with American Neurological Association that is relevant to AAN interests or activities. Dr. Feldman has a non-compensated relationship as a Membership Committee Member, Strategic Planning Committee Member, Chair of Section 07, Neuroscience Forum, Council Member with National Academy of Medicine that is relevant to AAN interests or activities. Dr. Feldman has a non-compensated relationship as a Committee on Making ALS a Livable Disease Member with National Academy of Sciences, Engineering, and Medicine that is relevant to AAN interests or activities. Dr. Feldman has a non-compensated relationship as a Member, Blueprint Neurotherapeutics Network for Biologics (BPN-Biologics) External Oversight Committee with National Institutes of Health that is relevant to AAN interests or activities.
Stephen Goutman, MD, FAAN	Dr. Goutman has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Evidera. The institution of Dr. Goutman has received research support from National Institutes of Health. The institution of Dr. Goutman has received research support from ALS Association. The institution of Dr. Goutman has received research support from CDC. Dr. Goutman has received intellectual property interests from a discovery or technology relating to health care.
Zachary Simmons, MD, FAAN	Dr. Simmons has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Amylyx. Dr. Simmons has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Clene. Dr. Simmons has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Insmed. Dr. Simmons has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Dr. Simmons has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Corcept. The institution of Dr. Simmons has received personal compensation in the range of $50,000-$99,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Wiley. The institution of Dr. Simmons has received research support from MGH. The institution of Dr. Simmons has received research support from Clene. The institution of Dr. Simmons has received research support from NIH via MGH. The institution of Dr. Simmons has received research support from Aburo. The institution of Dr. Simmons has received research support from NIH subaward via Univ of Pennsylvania.

��ɫ��

��ɫ��